Hear hear! Ear gene therapy player Akouos draws $105M in fresh capital
Come on, come on, listen to the money talk.
Thriving on the momentum of biotechnology companies working on therapies to address hearing loss, Boston-based Akouos has scored $105 million in an oversubscribed Series B financing, less than two years after an NEA, 5AM Ventures-backed $50 million haul.
Akouos — Greek for ‘to hear’ — is developing gene therapies engineered to restore, improve or preserve hearing. Along with its partners — the world’s largest hearing research center Massachusetts Eye and Ear, as well as Swiss Alps-based viral gene and cell therapy maker Lonza — Akouos is at the cusp of taking its lead therapy into the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.